BEDFORD, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. ANIKa global joint preservation company in early intervention orthopedics, announced today that the company plans to release its third quarter 2022 financial results after the market close on Tuesday, November 8, 2022 and the same day at 5:00 p.m ET to discuss financial results and business highlights.
You can access the conference call by dialing 1-888-256-1007 (domestic toll-free) or 1-856-344-9221 (international) and quoting the conference ID number 2205523. A live audio webcast will be available in Investor Relations section of Anika’s website, www.anika.com. An accompanying slide presentation is also available on the Anika website. The call for proposals will be archived shortly after completion and will be accessible on the same website.
About Anika
Anika Therapeutics, Inc. ANIK, is a global joint preservation company that develops and delivers significant advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that are bringing people around the world back to an active life. Our focus is on high-potential areas within orthopedics, including osteoarthritis pain management, regenerative solutions, sports medicine soft tissue repair and bone-preserving joint technologies, and our products are efficiently delivered at key care locations, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, see www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc.
For investor inquiries:
Anika Therapeutics, Inc.
Mark Namaroff, 781-457-9287
Vice President, Investor Relations, ESG and Corporate Communications
investorrelations@anika.com
